A citation-based method for searching scientific literature

Christopher K Cain, Margaret McCue, Iruma Bello, Timothy Creedon, Dei-In Tang, Eugene Laska, Donald C Goff. Schizophr Res 2014
Times Cited: 52







List of co-cited articles
807 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.
Robert W Buchanan, Daniel C Javitt, Stephen R Marder, Nina R Schooler, James M Gold, Robert P McMahon, Uriel Heresco-Levy, William T Carpenter. Am J Psychiatry 2007
293
44

Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study.
Donald C Goff, Corinne Cather, Jennifer D Gottlieb, A Eden Evins, Jared Walsh, Lisa Raeke, Michael W Otto, David Schoenfeld, Michael F Green. Schizophr Res 2008
94
44

Feasibility, safety, and efficacy of the combination of D-serine and computerized cognitive retraining in schizophrenia: an international collaborative pilot study.
Deepak C D'Souza, Rajiv Radhakrishnan, Edward Perry, Savita Bhakta, Nagendra M Singh, Richa Yadav, Danielle Abi-Saab, Brian Pittman, Santosh K Chaturvedi, Mahendra P Sharma,[...]. Neuropsychopharmacology 2013
50
44

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Mark Weiser, Uriel Heresco-Levy, Michael Davidson, Daniel C Javitt, Nomi Werbeloff, Ari A Gershon, Yehuda Abramovich, Daniela Amital, Adiel Doron, Shai Konas,[...]. J Clin Psychiatry 2012
67
32

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
J H Krystal, L P Karper, J P Seibyl, G K Freeman, R Delaney, J D Bremner, G R Heninger, M B Bowers, D S Charney. Arch Gen Psychiatry 1994
32

D-serine added to antipsychotics for the treatment of schizophrenia.
G Tsai, P Yang, L C Chung, N Lange, J T Coyle. Biol Psychiatry 1998
505
32

Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Hsien-Yuan Lane, Ching-Hua Lin, Michael F Green, Gerhard Hellemann, Chih-Chia Huang, Po-Wei Chen, Rene Tun, Yue-Cung Chang, Guochuan E Tsai. JAMA Psychiatry 2013
134
28

D-cycloserine facilitation of cognitive behavioral therapy for delusions in schizophrenia.
Jennifer D Gottlieb, Corinne Cather, Meghan Shanahan, Timothy Creedon, Eric A Macklin, Donald C Goff. Schizophr Res 2011
52
28

A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients.
Donald C Goff, Lawrence Herz, Thomas Posever, Vivian Shih, Guochuan Tsai, David C Henderson, Oliver Freudenreich, A Eden Evins, Iftah Yovel, Hui Zhang,[...]. Psychopharmacology (Berl) 2005
86
26

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.
D C Goff, G Tsai, J Levitt, E Amico, D Manoach, D A Schoenfeld, D L Hayden, R McCarley, J T Coyle. Arch Gen Psychiatry 1999
308
26

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.
Uriel Heresco-Levy, Daniel C Javitt, Richard Ebstein, Agnes Vass, Pesach Lichtenberg, Gali Bar, Sara Catinari, Marina Ermilov. Biol Psychiatry 2005
267
25

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Daniel Umbricht, Daniela Alberati, Meret Martin-Facklam, Edilio Borroni, Eriene A Youssef, Michael Ostland, Tanya L Wallace, Frédéric Knoflach, Ernest Dorflinger, Joseph G Wettstein,[...]. JAMA Psychiatry 2014
138
25

Effects of D-cycloserine on negative symptoms in schizophrenia.
Erica J Duncan, Sandor Szilagyi, Marion P Schwartz, Dragana Bugarski-Kirola, Alena Kunzova, Shobhit Negi, Myrsini Stephanides, Toby R Efferen, Burt Angrist, Eric Peselow,[...]. Schizophr Res 2004
72
25

A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy.
Melissa M Norberg, John H Krystal, David F Tolin. Biol Psychiatry 2008
323
23

High dose D-serine in the treatment of schizophrenia.
Joshua T Kantrowitz, Anil K Malhotra, Barbara Cornblatt, Gail Silipo, Andrea Balla, Raymond F Suckow, Cyril D'Souza, John Saksa, Scott W Woods, Daniel C Javitt. Schizophr Res 2010
158
23


Recent advances in the phencyclidine model of schizophrenia.
D C Javitt, S R Zukin. Am J Psychiatry 1991
21

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.
U Heresco-Levy, D C Javitt, M Ermilov, C Mordel, G Silipo, M Lichtenstein. Arch Gen Psychiatry 1999
356
21

Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Hsien-Yuan Lane, Yue-Cune Chang, Yi-Ching Liu, Chih-Chiang Chiu, Guochuan E Tsai. Arch Gen Psychiatry 2005
209
21

D-serine added to clozapine for the treatment of schizophrenia.
G E Tsai, P Yang, L C Chung, I C Tsai, C W Tsai, J T Coyle. Am J Psychiatry 1999
165
21

Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
Chun-Yuan Lin, Sun-Yuan Liang, Yue-Cune Chang, Shuo-Yen Ting, Ching-Ling Kao, Yu-Hsin Wu, Guochuan E Tsai, Hsien-Yuan Lane. World J Biol Psychiatry 2017
50
22

Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia.
Guochuan Tsai, Hsien-Yuan Lane, Pinchen Yang, Mian-Yoon Chong, Nicholas Lange. Biol Psychiatry 2004
259
19

A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes.
Til Wykes, Vyv Huddy, Caroline Cellard, Susan R McGurk, Pál Czobor. Am J Psychiatry 2011
961
19


A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia.
Hsien-Yuan Lane, Ching-Hua Lin, Yu-Jhen Huang, Chun-Hui Liao, Yue-Cune Chang, Guochuan E Tsai. Int J Neuropsychopharmacol 2010
125
19

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia.
Uriel Heresco-Levy, Marina Ermilov, Jonathan Shimoni, Baruch Shapira, Gail Silipo, Daniel C Javitt. Am J Psychiatry 2002
146
19

Effects of multiple exposures to D-cycloserine on extinction of conditioned fear in rats.
A Sophie Parnas, Marianne Weber, Rick Richardson. Neurobiol Learn Mem 2005
115
17

Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention.
D Quartermain, J Mower, M F Rafferty, R L Herting, T H Lanthorn. Eur J Pharmacol 1994
148
17


D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study.
B N van Berckel, C N Evenblij, B J van Loon, M F Maas, M A van der Geld, H J Wynne, J M van Ree, R S Kahn. Neuropsychopharmacology 1999
62
17


D-serine for the treatment of negative symptoms in individuals at clinical high risk of schizophrenia: a pilot, double-blind, placebo-controlled, randomised parallel group mechanistic proof-of-concept trial.
Joshua T Kantrowitz, Scott W Woods, Eva Petkova, Barbara Cornblatt, Cheryl M Corcoran, Huaihou Chen, Gail Silipo, Daniel C Javitt. Lancet Psychiatry 2015
91
17


Improvement in mismatch negativity generation during d-serine treatment in schizophrenia: Correlation with symptoms.
Joshua T Kantrowitz, Michael L Epstein, Migyung Lee, Nayla Lehrfeld, Karen A Nolan, Constance Shope, Eva Petkova, Gail Silipo, Daniel C Javitt. Schizophr Res 2018
53
17

Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.
Kerry J Ressler, Barbara O Rothbaum, Libby Tannenbaum, Page Anderson, Ken Graap, Elana Zimand, Larry Hodges, Michael Davis. Arch Gen Psychiatry 2004
697
15

The N-methyl-D-aspartate receptor co-agonist D-cycloserine facilitates declarative learning and hippocampal activity in humans.
Oezguer A Onur, Thomas E Schlaepfer, Juraj Kukolja, Andreas Bauer, Haang Jeung, Alexandra Patin, David-Marian Otte, N Jon Shah, Wolfgang Maier, Keith M Kendrick,[...]. Biol Psychiatry 2010
68
15

Amelioration of negative symptoms in schizophrenia by glycine.
D C Javitt, I Zylberman, S R Zukin, U Heresco-Levy, J P Lindenmayer. Am J Psychiatry 1994
286
15

D-alanine added to antipsychotics for the treatment of schizophrenia.
Guochuan E Tsai, Pinchen Yang, Yue-Cune Chang, Mian-Yoon Chong. Biol Psychiatry 2006
135
15

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial.
Michael Berk, David Copolov, Olivia Dean, Kristy Lu, Sue Jeavons, Ian Schapkaitz, Murray Anderson-Hunt, Fiona Judd, Fiona Katz, Paul Katz,[...]. Biol Psychiatry 2008
364
15

Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia.
Melissa Fisher, Christine Holland, Michael M Merzenich, Sophia Vinogradov. Am J Psychiatry 2009
292
15


D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia.
A Eden Evins, Ed Amico, Thomas A Posever, Rob Toker, Donald C Goff. Schizophr Res 2002
98
15

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.
U Heresco-Levy, D C Javitt, M Ermilov, C Mordel, A Horowitz, D Kelly. Br J Psychiatry 1996
198
15


Placebo-controlled trial of glycine added to clozapine in schizophrenia.
A E Evins, S M Fitzgerald, L Wine, R Rosselli, D C Goff. Am J Psychiatry 2000
128
15

Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later.
Melissa Fisher, Christine Holland, Karuna Subramaniam, Sophia Vinogradov. Schizophr Bull 2010
152
15

A meta-analysis of cognitive remediation in schizophrenia.
Susan R McGurk, Elizabeth W Twamley, David I Sitzer, Gregory J McHugo, Kim T Mueser. Am J Psychiatry 2007
709
15

Neurophysiological Effects of Bitopertin in Schizophrenia.
Joshua T Kantrowitz, Karen A Nolan, Michael L Epstein, Nayla Lehrfeld, Constance Shope, Eva Petkova, Daniel C Javitt. J Clin Psychopharmacol 2017
19
42

Structural determinants of D-cycloserine efficacy at the NR1/NR2C NMDA receptors.
Shashank M Dravid, Pieter B Burger, Anand Prakash, Matthew T Geballe, Roopali Yadav, Phuong Le, Kimberly Vellano, James P Snyder, Stephen F Traynelis. J Neurosci 2010
77
13

Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis.
Harri J Tuominen, Jari Tiihonen, Kristian Wahlbeck. Schizophr Res 2005
150
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.